Amcor (AMCR) Q4 2026 Earnings Call Transcript

Amcor reported Q4 adjusted EPS of $1.23, up 23% YoY, alongside net sales of $6.4B (+26% reported) and adjusted EBITDA of $1.045B (+32%). Synergy delivery accelerated: $115M realized in Q4 and $285M for fiscal 2026, ~10% ahead of initial expectations, with management reaffirming the $650M 3-year target. The firm guided adjusted EPS for the 6 months ending Dec. 31, 2026 at $1.80–$1.90 and expects leverage to fall to ~3.0x by end-2027 despite a ~$500M working-capital drag tied to the Middle East conflict. Shares likely benefit from the combination of strong integration progress (Berry acquisition), improved segment margins, and a clear path to double-digit calendar 2027 EPS growth.

Analysis

The near-term read-through is more about cash conversion than headline EPS. If the working-capital drag reverses over the next 2-4 quarters, AMCR can mechanically de-lever faster than the market likely models, and that matters because packaging equities tend to re-rate when balance-sheet risk fades. The equity story is therefore less "earnings momentum" and more "credit spread compression via FCF inflection," which can support multiple expansion even if volumes only stay flat to modestly positive.

Second-order winners are the integrated, scale players that can bundle bottles, closures, pumps, and pharma-format packaging; that raises switching costs and makes it harder for smaller regional converters to compete on price. The revenue synergy pipeline also suggests incremental share gains in beauty/wellness, pet care, foodservice, and GLP-1-adjacent packaging, where breadth beats point-solution suppliers. The losers are levered standalone packaging names with weaker procurement leverage and less ability to absorb resin/logistics volatility.

Contrarian risk: the market may be over-penalizing the stock for macro weakness while underpricing how much of the 2027 upside is already being "pre-claimed" by management math. The cleanest falsifier is not EPS but cash: if DSO/inventory do not normalize and leverage stays above ~3.4x into mid-2027, the thesis that this is a self-help deleveraging story breaks. Also, if July-to-fall volumes slip back below flat, the revenue synergy narrative becomes a margin-only story and the stock likely stalls.

Key Decisions for Investors

• Buy AMCR on a 3-5% post-earnings pullback; use a 6-12 month horizon for the deleveraging thesis. Upside is driven by FCF normalization and a path from ~3.5x to ~3.0x leverage; falsify if working capital does not unwind by the next two quarters.
• For higher conviction, add to AMCR only if September-quarter commentary confirms flat-to-up volumes and cash recovery starts to show in receivables/inventory. If those data points miss, cut the position rather than waiting for 2027 guidance.
• Pair idea: long AMCR / short SON on the view that scale integration and revenue synergies favor the larger global platform over a more commoditized packaging peer. Target is 3-6 months; stop if AMCR loses volume momentum or SON shows materially better organic growth.
• Watch-item alert: if raw-material deflation accelerates but AMCR fails to show margin capture, that would imply pricing discipline is weaker than management suggests and the stock should be treated as a hold, not a buy.